Clinical Trials Logo

Clinical Trial Summary

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are limitations of CAR-T cells, the consuming manufacturing time and expensive price exclude the majority of patients. therefore, we designed this trial to manifest the safety and efficacy of anti-CD19 CAR NK cell therapy in non-Hodgkin lymphoma


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04639739
Study type Interventional
Source Xinqiao Hospital of Chongqing
Contact Xi Zhang, MD phD
Phone 13808310064
Email zhangxxi@sina.com
Status Not yet recruiting
Phase Early Phase 1
Start date December 17, 2020
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04555811 - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Phase 1
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT03535753 - Safety and Efficacy Evaluation of Decitabine With R-GDP Phase 1
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Completed NCT00513175 - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia N/A
Recruiting NCT05641428 - Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL Phase 2
Active, not recruiting NCT05879744 - A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Phase 1
Completed NCT00342121 - Influence of Corn Farming on the Immune System
Withdrawn NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Phase 1/Phase 2
Active, not recruiting NCT04139252 - A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients
Recruiting NCT04440436 - Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients Phase 1/Phase 2
Terminated NCT04840784 - First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML Phase 1
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1
Terminated NCT02702492 - PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Phase 1
Completed NCT03527147 - Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) Phase 1
Withdrawn NCT05365100 - A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL Phase 1/Phase 2
Terminated NCT00814983 - Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Phase 1/Phase 2
Withdrawn NCT02847949 - A Study of IGN002 for Refractory NHL Phase 1
Completed NCT00891592 - Umbilical Cord Blood Transplant for Hematological Malignancies Phase 1
Completed NCT00546793 - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Phase 1/Phase 2